Abstract
Acute Myeloid Leukemia (AML) is a cancer originated from the accumulation of immature hematopoietic cells (blasts) in the bone marrow, characterized by low rates of patient survival. Mutations in the tumor suppressing gene TP53 are present in around 5-10% of AML cases and are associated with a worse prognosis. It is believed that the additional patients present inactivation of the TP53 pa…